Equillium Inc (EQ)
0.711
-0.01
(-1.25%)
USD |
NASDAQ |
Nov 22, 16:00
0.7306
+0.02
(+2.76%)
After-Hours: 20:00
Equillium Revenue (TTM): 45.91M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 45.91M |
| June 30, 2024 | 42.62M |
| March 31, 2024 | 37.89M |
| Date | Value |
|---|---|
| December 31, 2023 | 36.08M |
| September 30, 2023 | 42.63M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
36.08M
Minimum
Dec 2023
45.91M
Maximum
Sep 2024
41.03M
Average
42.62M
Median
Jun 2024
Revenue (TTM) Benchmarks
| Matinas BioPharma Holdings Inc | -- |
| Tenon Medical Inc | 3.315M |
| Alphatec Holdings Inc | 572.74M |
| Madrigal Pharmaceuticals Inc | -- |
| Spero Therapeutics Inc | 89.86M |